Features | Healtcare News | BioTuesdays by Kilmer Lucas IR

This Week's Feature

HDT Bio focused on global impact of mRNA vaccine platform

HDT Bio is developing messenger RNA vaccines addressing diverse indications in infectious diseases and oncology, and is utilizing regional partnerships for manufacturing, clinical development and commercialization.

May 23, 2023

Feature

ADvantage Therapeutics taking disruptive approach to mild Alzheimer’s

Closely-held ADvantage Therapeutics is awaiting regulatory approval in Europe to proceed with a Phase 2b confirmatory clinical trial of its lead drug candidate, AD04, for the treatment of mild Alzheimer’s disease (AD).

May 16, 2023

Feature

Peptilogics lead peptide platform targeting serious joint replacement infections

Peptilogics is working to change the treatment paradigm of periprosthetic joint infection (PJI), a serious condition that can result from joint replacement surgery. The company is preparing for a registrational clinical...

May 9, 2023

Feature

SynaptixBio targeting rare disease, TUBB4A leukodystrophy, virtually

UK based biotechnology company SynaptixBio is developing the world’s first life-saving medicine for TUBB4A leukodystrophy, a rare genetic neurodegenerative disease that affects approximately 1,600 newborn babies and...

May 2, 2023

Feature

EyePoint focused on long-lasting treatments for wet AMD and DR

EyePoint Pharmaceuticals (NASDAQ:EYPT) is advancing its lead drug candidate, EYP-1901, in two Phase 2 clinical trials as a potential six-month treatment for wet age-related macular degeneration (AMD) and a potential...

April 25, 2023

Feature

Alaunos attacking solid tumors with cutting-edge TCR-T cell therapies

Alaunos Therapeutics (NASDAQ:TCRT) is developing a library of T-cell receptor (TCR) cell therapies with the potential to revolutionize the treatment of solid tumors.

April 18, 2023

Feature

Rezolute focused on paradigm shift treating DME

Rezolute (NASDAQ:RZLT) is working on therapies targeting both ends of the spectrum of dysregulated glucose. It has now entered Phase 2 with an oral therapy to treat diabetic macular edema (DME), a big market...

April 11, 2023

Feature

KeifeRx developing oral TKIs for neurodegenerative and immune diseases

Closely-held KeifeRx is developing optimized, low dose, oral tyrosine kinase inhibitors (TKIs) for the treatment of multiple neurodegenerative and immune diseases.

April 4, 2023

Feature

BioStem Technologies harnessing perinatal tissue for regenerative therapies

Fresh from a decision by the Center for Medicare Services to establish national pricing for its VENDAJE allografts for regenerative therapies, BioStem Technologies (OTCQB:BSEM) is gearing up for a new spurt of growth.

March 28, 2023

Feature

Enveric taking new approach to mental health challenges

Enveric Biosciences (NASDAQ:ENVB) has created a library of more than 500 new chemical entities from its drug platform, including next generation psilocybin analogues for the treatment of anxiety, depression, and...

March 21, 2023

Feature

bioAffinity rolling out CyPath for early detection of lung cancer

bioAffinity Technologies (NASDAQ:BIAF) is rolling out CyPath Lung, an accurate, non-invasive and cost-effective test for the early detection of lung cancer, in the U.S. Southwest before a staged nationwide launch.

March 14, 2023

Feature

Conavi’s Novasight shines new light on coronary interventions

Privately-held Conavi Medical’s Novasight Hybrid System represents a breakthrough imaging platform for use by interventional cardiologists during common minimally invasive heart procedures.

March 7, 2023

Feature

AUM Biosciences focused on reversing cancer resistance

With two clinical and two preclinical assets, AUM Biosciences is developing precision oncology therapeutics designed to reverse cancer resistance through multi-targeting approaches.

February 28, 2023

Feature

Cognition Therapeutics focused on modifying degenerative disorders

As the recipient of more than $170-million of non-dilutive grant funding, Cognition Therapeutics (NASDAQ:CGTX) is developing disease-modifying medicines for neurodegenerative disorders, such as Alzheimer's disease (AD)...

February 21, 2023

Feature

Context Therapeutics advancing pipeline for female cancers and other tumors

Martin Lehr likes to use a baseball analogy to describe his company’s two cancer programs. “CTIM-76 is our hot young rookie with home run potential at every bat while ONA-XR is our veteran who consistently gets on...

February 14, 2023

Feature

Indaptus advancing Decoy20 against metastatic solid tumors

Indaptus Therapeutics (NASDAQ:INDP) is conducting a first-in-human, dose escalation Phase 1 study of its lead compound, Decoy20, in patients with advanced metastatic solid tumors where currently approved therapies have...

February 7, 2023

Feature

Stephanie Willerth talks up award winning bioink start-up

As CEO and co-founder of closely-held Axolotl Biosciences, Stephanie Willerth, Ph.D., also is a full professor of biomedical engineering at the University of Victoria, British Columbia, where she runs a research lab...

January 31, 2023

Feature

Azura targeting ophthalmic keratolytics for ocular surface diseases

After posting positive Phase 2b results in November, Azura Ophthalmics plans to launch a Phase 3 registration trial in mid-2023 with its lead ointment, AZR-MD-001, for the treatment of meibomian gland dysfunction (MGD)...

January 24, 2023

Feature

Reneo targeting rare genetic mitochondrial diseases with unmet need

Reneo Pharmaceuticals (NASDAQ:RPHM) is conducting a pivotal Phase 2b clinical trial with its lead asset, REN001, in a rare genetic disease that predominately affects skeletal muscle and reduces life expectancy, with...

January 17, 2023

Feature

SeaStar Medical gears for Q1 FDA decision on device to reverse effects of hyperinflammation

SeaStar Medical (NASDAQ:ICU) expects an FDA decision in the first quarter on a humanitarian device exemption application to use its Selective Cytopheretic Device (SCD) to treat the life-threatening effects of...

January 10, 2023

Feature

Theralase advances pivotal clinical study of photo dynamic therapy to treat bladder cancer

Theralase Technologies (TSXV:TLT; OTCQB:TLTFF) expects to complete enrollment and primary study treatment in early 2024 of a Phase 2 pivotal clinical study for non-muscle invasive bladder cancer (NMIBC) with its light...

January 3, 2023

Feature

OcuTerra advancing eye drop for earlier treatment of diabetic retinopathy

Closely-held OcuTerra Therapeutics is conducting a Phase 2 clinical study of a novel eye drop for earlier, non-invasive treatment of patients with moderate-to-severe diabetic retinopathy to preserve vision.

December 13, 2022

HDT Bio focused on global impact of mRNA vaccine platform

ADvantage Therapeutics taking disruptive approach to mild Alzheimer’s

Peptilogics lead peptide platform targeting serious joint replacement infections

SynaptixBio targeting rare disease, TUBB4A leukodystrophy, virtually

EyePoint focused on long-lasting treatments for wet AMD and DR

Alaunos attacking solid tumors with cutting-edge TCR-T cell therapies

Rezolute focused on paradigm shift treating DME

KeifeRx developing oral TKIs for neurodegenerative and immune diseases

BioStem Technologies harnessing perinatal tissue for regenerative therapies

Enveric taking new approach to mental health challenges

bioAffinity rolling out CyPath for early detection of lung cancer

Conavi’s Novasight shines new light on coronary interventions

AUM Biosciences focused on reversing cancer resistance

Cognition Therapeutics focused on modifying degenerative disorders

Context Therapeutics advancing pipeline for female cancers and other tumors

Indaptus advancing Decoy20 against metastatic solid tumors

Stephanie Willerth talks up award winning bioink start-up

Azura targeting ophthalmic keratolytics for ocular surface diseases

Reneo targeting rare genetic mitochondrial diseases with unmet need

SeaStar Medical gears for Q1 FDA decision on device to reverse effects of hyperinflammation

Theralase advances pivotal clinical study of photo dynamic therapy to treat bladder cancer

OcuTerra advancing eye drop for earlier treatment of diabetic retinopathy

General

More